FIELD: chemistry, pharmacology.
SUBSTANCE: described are novel pyridopyrrolizine and pyridoindolizine derivatives of general formula I 
and their pharmaceutically acceptable salts and hydrates, where A is C1-3alkyl; Ar stands for naphtyl or phenyl optionally substituted with one or two groups, selected from halogen, C1-6alkyl or C1-6alkyl haloid; Q stands for COOH; one of X1, X2, X3 or X4 stands for nitrogen, others are independently selected from CH and C-Rg, where Rg stands for C1-6alkyl or S(O)nC1-6alkyl, where n=0, 2; Y1 stands for S or C(O); Y2 stands for (CRdRe)m, where Rd and Re - hydrogen, m is integer 1 or 2; R1, R2, R3 stands for hydrogen, pharmaceutical composition, containing them, and method of treatment of diseases, mediated by prostaglandin D2.
EFFECT: obtaining novel pyridopyrrolizine and pyridoindolizine derivatives which possess useful properties.
22 cl, 2 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | 2008 |
|
RU2451019C2 |
| INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
| ANTIVIRAL REMEDIES FOR TREATMENT AND PREVENTION OF HIV INFECTION | 2021 |
|
RU2780103C1 |
| NOVEL CONDENSED PYRIDINE DERIVATIVES USED AS C-MET TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619130C2 |
| PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2017 |
|
RU2721774C1 |
| PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN POSITION 6, THEIR OBTAINING AND APPLICATION IN THERAPY | 2005 |
|
RU2364595C2 |
| ANTIVIRAL REMEDIES FOR TREATMENT AND PREVENTION OF HIV INFECTION | 2020 |
|
RU2780101C2 |
| INHIBITORS OF AKT ACTIVITY | 2010 |
|
RU2579513C2 |
| 2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2005 |
|
RU2417990C2 |
| HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2015 |
|
RU2711502C2 |
